Full Text:
<87>
CLC number:
On-line Access: 2024-11-05
Received: 2024-03-13
Revision Accepted: 2024-08-28
Crosschecked: 0000-00-00
Cited: 0
Clicked: 165
Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies
| |||||||||||||
Muhammad SHOAIB, Zeeshan Ahmad BHUTTA, Ahsan JAVED, Muhammad Nabeel AMJAD, Wenzhu LI, Kyung-Chul CHOI, Wanxia PU. Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .
@article{title="Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies",
author="Muhammad SHOAIB, Zeeshan Ahmad BHUTTA, Ahsan JAVED, Muhammad Nabeel AMJAD, Wenzhu LI, Kyung-Chul CHOI, Wanxia PU",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2400146"
}
%0 Journal Article
%T Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies
%A Muhammad SHOAIB
%A Zeeshan Ahmad BHUTTA
%A Ahsan JAVED
%A Muhammad Nabeel AMJAD
%A Wenzhu LI
%A Kyung-Chul CHOI
%A Wanxia PU
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2400146
TY - JOUR
T1 - Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies
A1 - Muhammad SHOAIB
A1 - Zeeshan Ahmad BHUTTA
A1 - Ahsan JAVED
A1 - Muhammad Nabeel AMJAD
A1 - Wenzhu LI
A1 - Kyung-Chul CHOI
A1 - Wanxia PU
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2400146
Abstract: poly(ADP-ribose) polymerase (PARP) is a family of proteins that play a crucial role in diverse cellular processes, including DNA repair, cell death, and changes in chromatin structure. PARP inhibitors (PARPi) have been recognised as notable agents in the realm of anticancer therapeutics owing to their capacity to specifically impact DNA repair pathways, thereby inducing targeted death of cancerous cells, particularly in cancers with homologous recombination deficiencies (HRD). These inhibitors have been approved for the treatment of several cancers, such as ovarian, breast, and pancreatic cancers. Despite their promising therapeutic attributes, developing resistance to PARPi presents a formidable obstacle, curtailing their overall efficacy. This article presents a comprehensive description of the potential mechanisms related to PARPi resistance, an in-depth study of potential strategies to overcome resistance, and an assessment of the therapeutic potential of the PARPi in combination with alternative therapies.
Open peer comments: Debate/Discuss/Question/Opinion
<1>